The BPC provides support to over 90 clinical trials annually and receives and processes over 28,000 biological samples each year including blood, urine, cerebrospinal fluid, pleural effusion aspirate, ascites, saliva, and bone marrow aspirate. This Core is responsible for the management and repository of samples from the CCR clinics. Upon arrival, all samples are processed according to the clinical protocol (per standard operating procedures), barcoded and entered into a database for sample handling and storage purposes and cataloged into a software system. The BPC handles urgent same-day and routine sample shipments to both intramural and extramural laboratories. The BPC provides a broad range of services including the development and validation of procedures for specimen processing, analyses, and DNA extraction to establish protocols that optimize specimen integrity and consistency. In addition to laboratory services, the Core serves as a resource for clinicians seeking advice on study design including specimen collection and storage methods as well as all protocol-associated study worksheets related to data and sample collection. The BPC provides services related to sample processing, barcoding, and storage of pharmacokinetic (PK) and pharmacodynamic (PD) biospecimens for all trials. Staff provides support to clinical teams throughout the life cycle of their protocols including assistance with ensuring time-sensitive samples are collected appropriately and with provision of sample data and shipment logs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Scientific Cores Intramural Research (ZIC)
Project #
1ZICSC006536-25
Application #
9780274
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
25
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Clinical Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
Jackson, Sadhana; Weingart, Jon; Nduom, Edjah K et al. (2018) The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. Fluids Barriers CNS 15:2
Lee, Jung-Min; Peer, Cody J; Yu, Minshu et al. (2017) Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer. Clin Cancer Res 23:1397-1406
Lee, Jung-Min; Hays, John L; Chiou, Victoria L et al. (2017) Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer. Oncotarget 8:79175-79187
Dao, Kim; Chtioui, Haithem; Lu, Yimin et al. (2017) Pharmacokinetics of Pomalidomide in a Patient Receiving Hemodialysis Using a High-Cutoff Filter. Am J Kidney Dis 69:553-554
Dao, Kim; Lu, Yimin; Peer, Cody J et al. (2017) Pharmacokinetics of lenalidomide during high cut-off dialysis in a patient with multiple myeloma and renal failure. Cancer Chemother Pharmacol 79:215-218
Manasanch, Elisabet E; de Larrea, Carlos Fernández; Zingone, Adriana et al. (2017) Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone. Leuk Lymphoma 58:639-645
Ferraz Nogueira Filho, Marco A; Peer, Cody J; Nguyen, Jeffers et al. (2017) A simple and rapid UHPLC-MS/MS method for the quantitation of the dual aurora kinase A/B inhibitor SCH-1473759 in murine plasma. J Pharm Biomed Anal 132:223-226
Lee, Jung-Min; Cimino-Mathews, Ashley; Peer, Cody J et al. (2017) Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escala J Clin Oncol 35:2193-2202
Uldrick, Thomas S; Gonçalves, Priscila H; Wyvill, Kathleen M et al. (2017) A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma. Oncologist 22:505-e49
Goey, Andrew K L; Sissung, Tristan M; Peer, Cody J et al. (2016) Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer. J Clin Pharmacol 56:461-73

Showing the most recent 10 out of 43 publications